CHRONIC LYMPHOCYTIC LEUKEMIA

This study tests a vaccine designed to protect people who have had a stem cell transplant from a common virus called CMV. The virus can cause serious illness in those with weak immune systems. The vaccine uses a harmless virus to teach the body to fight CMV, aiming to reduce infe…

This study tests a vaccine called Triplex to prevent cytomegalovirus (CMV) infection in adults who have received a stem cell transplant. CMV can cause serious illness in people with weakened immune systems. The vaccine uses harmless pieces of CMV DNA to help the body build immuni…

This study tests different COVID-19 booster vaccines in 960 immunocompromised people, including those with HIV, organ transplants, or blood cancers. The goal is to find which booster schedule gives the strongest and safest immune response. Results will help doctors protect these …

This study compares a new oral drug, nemtabrutinib, against standard chemotherapy combinations for people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a specific genetic change (TP53 mutation). About 300 particip…

This study tested a combination of two drugs, ibrutinib and fludarabine, in 29 people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Participants took ibrutinib daily and received fludarabine for a short time. The goal was to see how many patients achi…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The goal is to track long-term safety and side effects. About 165 adults are taking part, and they must continue to tolerate the drug well.

This study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphoma) that have returned or not responded to prior treatments. The drug delivers radiation directly to cancer cells. A…

This study tests a stem cell transplant using donors who are not a perfect match for people with blood cancers like leukemia or lymphoma. The goal is to see if adding certain drugs after the transplant can prevent complications and improve survival. About 300 adults and children …

This phase 3 study tests whether the targeted drug zanubrutinib works better than the standard combination of bendamustine and rituximab for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. About 590 participants who cannot take stronger chemo wil…

This study tested a stem cell transplant using blood stem cells from a half-matched (haploidentical) donor for people with blood cancers like leukemia and lymphoma. The goal was to see how many patients survived and had successful engraftment by 100 days and one year after transp…

This study tests a new drug, IPI-145, added to standard chemotherapy (FCR) for younger adults (ages 18-65) with untreated chronic lymphocytic leukemia (CLL). The goal is to see if the combination is safe and can make cancer cells undetectable in the bone marrow. About 32 particip…

This study tests whether adding a new targeted drug, pirtobrutinib, to standard therapy (venetoclax and rituximab) can help people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already received treatment. About 600 participants will receive …

This study tests a combination of two drugs, ibrutinib and obinutuzumab, in people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. The main goal is to check the safety of different doses. About 54 adults with CLL or a related lymphom…

This study tests a combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab as the first treatment for people with chronic lymphocytic leukemia (CLL) who have a specific genetic marker (mutated IGHV) and no deletion in chromosome 17. The goal is to see if this dr…

This study tests whether people with chronic lymphocytic leukemia (CLL) can safely start venetoclax faster than the usual 5-week schedule. About 40 patients with new or returning CLL will take venetoclax daily with a quicker dose increase. The goal is to see if this faster approa…

This study looks at how long people with chronic lymphocytic leukemia (CLL) stay on the drug acalabrutinib when it's used in regular medical practice in Italy. Researchers will track 151 patients who started the drug between 2021 and 2022, noting why some stop treatment. The goal…

This early-phase study tests a new treatment for people with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment uses the patient's own T cells, which are modified in the lab to recognize and attack cancer cells carrying a protein cal…

This early-stage study tests a new treatment called SC291 for people with certain types of blood cancers (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. SC291 is a type of CAR T cell therapy made from donor cel…

This study tested a newer targeted drug called acalabrutinib against two standard combination therapies (idelalisib plus rituximab or bendamustine plus rituximab) in 310 adults with chronic lymphocytic leukemia (CLL) that had come back or stopped responding to prior treatment. Th…

This study tests whether combining two targeted drugs, venetoclax and ibrutinib, can better control chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It includes 234 patients whose cancer has returned or is hard to treat, as well as some untreated high-risk …

This study tests a combination of two drugs, tafasitamab and zanubrutinib, in people newly diagnosed with CLL or SLL. The goal is to see if this combination can kill more cancer cells than either drug alone. About 26 adults will take part, and researchers will measure how many ac…

This study tests whether adding cirmtuzumab to the standard drug venetoclax can eliminate remaining leukemia cells in people with chronic lymphocytic leukemia (CLL) who still have detectable disease after taking venetoclax alone. About 5 participants will receive the combination …

This study tests a new drug, MK-2140, alone or with other treatments, in people with certain B-cell blood cancers that have come back or not responded to prior therapy. About 223 adults with mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, or Richter trans…

This study tests whether adding venetoclax to a two-drug regimen (ibrutinib and obinutuzumab) helps younger patients with untreated chronic lymphocytic leukemia (CLL) live longer without their cancer worsening. About 720 participants will receive either the two-drug or three-drug…

This study tests whether combining venetoclax (a pill) with rituximab (an injection) can shrink or control chronic lymphocytic leukemia (CLL) that has come back or stopped responding to other treatments. About 25 adults with CLL will receive this combination. The goal is to see h…

This study tests a combination of two drugs, pirtobrutinib and venetoclax, for people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this treatment can reduce cancer to very low levels, measured by a sensitive blood test. The leng…

This study tests whether people with CLL or SLL can safely stop taking acalabrutinib and obinutuzumab once their cancer responds well, instead of staying on treatment indefinitely. The goal is to see if a break from therapy lowers side effects and prevents drug resistance. About …

This early-stage study tests a new drug called ABBV-525 in people with B-cell cancers like lymphoma and leukemia. The goal is to find a safe dose and see if it can shrink tumors. About 78 adults will take the drug by mouth at different doses over several months.

This study tests whether adding the targeted drug ibrutinib to standard chemotherapy (FCR) can help younger, untreated patients with chronic lymphocytic leukemia (CLL) achieve a very deep remission, where no cancer cells can be found in the bone marrow. About 85 participants will…

This study follows 192 adults in Spain with chronic lymphocytic leukemia (CLL) who started taking acalabrutinib for the first time. Researchers want to see how many patients stay on the drug after 24 months, especially those new to treatment or switching due to side effects from …

This early-phase study tests a new treatment called FT819 for people with certain blood cancers (B-cell lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia) that have not responded to standard therapies. The treatment uses specially engineered immune cells to…

This study tests a combination of two oral drugs, duvelisib and venetoclax, in 55 adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or Richter's Syndrome. The goal is to see how well the drugs work together to shrink or control the cancer. Participants must ha…

This study tests a combination of two drugs, ixazomib and rituximab, in people with slow-growing types of B-cell non-Hodgkin lymphoma. The goal is to see how well the drugs shrink or control the cancer. About 33 adults with various subtypes, including follicular lymphoma and chro…

This study tests whether adding venetoclax to ibrutinib can eliminate genetic mutations that make chronic lymphocytic leukemia (CLL) resistant to ibrutinib. About 28 adults with CLL who have developed these mutations while on ibrutinib will receive the combination for 12 cycles. …

This study looks at whether giving vitamin D supplements to cancer patients who have low vitamin D levels can improve their survival and delay the need for treatment. About 565 adults with certain types of lymphoma or leukemia are taking part. Researchers are comparing those who …

This study tests a drug called ACP-196 (acalabrutinib) in 60 adults with chronic lymphocytic leukemia (CLL) whose cancer returned or didn't respond to treatment and who had to stop ibrutinib due to side effects. The goal is to see if ACP-196 can shrink or control the cancer. Part…

This study tests a drug called acalabrutinib for people with chronic lymphocytic leukemia (CLL) who also have a type of anemia where the immune system attacks red blood cells. The goal is to see if the drug can control the anemia after other treatments have failed. Only 4 people …

This study tests whether the drug lenalidomide, combined with a vaccine, can help the immune system fight early-stage chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in people with high-risk genetic features. About 49 participants will receive the treatment…

This study tests a combination of three drugs (acalabrutinib, umbralisib, and ublituximab) in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. The goal is to see how many patients achieve complete remission after 24 cycles of treatment. The study incl…

This study compares a new oral drug, LOXO-305, to two standard treatment combinations (idelalisib plus rituximab or bendamustine plus rituximab) in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with a BTK inhibito…

This study tested whether a combination of ibrutinib (a targeted drug) and rituximab works better than standard chemotherapy (FCR) for younger patients with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. Over 500 participants were randomly assigned to…

This study tests a new treatment called rapcabtagene autoleucel (YTB323) for several types of blood cancer, including chronic lymphocytic leukemia, small lymphocytic lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. About 217 adults will receive this ther…

This early-phase study tests a new combination of two drugs, acalabrutinib and ceralasertib, in people with a high-risk form of chronic lymphocytic leukemia (CLL) that has come back or stopped responding to other treatments. The main goal is to check the safety and how well the d…

This study tests a new oral drug called ARQ 531 (nemtabrutinib) in about 190 people with certain blood cancers (like lymphoma or leukemia) that have returned or not responded to prior therapy. The goal is to find the safest dose and see if the drug can shrink tumors. Participants…

This study looks at whether adding the drug venetoclax to standard BTKi therapy can help people with chronic lymphocytic leukemia (CLL) reach very deep remission. The goal is to allow patients to stop treatment for a period. About 118 adults who have been on BTKi therapy for at l…

This early-phase study tests whether adding specially treated immune cells (called veto cells) from a donor can help stem cell transplants work better in people with blood cancers like leukemia or lymphoma. The goal is to help the donor cells grow without causing severe graft-ver…

This study tests whether adding sonrotoclax to zanubrutinib works better than zanubrutinib alone for adults with untreated chronic lymphocytic leukemia (CLL). About 94 participants will receive either the combination or the single drug. The goal is to see if the combo leads to mo…

This study tests a combination of three drugs—atezolizumab, obinutuzumab, and venetoclax—in about 50 adults with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma, or Richter syndrome that has returned or not responded to prior treatment. The goal is to see if the co…

This study tests a combination of three drugs (obinutuzumab, ibrutinib, and venetoclax) in people with chronic lymphocytic leukemia (CLL) that has come back, not responded to treatment, or is newly diagnosed. The goal is to find the safest dose and see if the combination can make…

This early-phase study tests an experimental oral drug called APG-2575 in adults with relapsed or hard-to-treat chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to check the drug's safety and find the best dose. About 74 participants will take t…

This phase 3 study compares two oral medications, acalabrutinib and ibrutinib, in adults with high-risk chronic lymphocytic leukemia (CLL) who have already received at least one prior treatment. The main goal is to see if acalabrutinib is as good as ibrutinib at delaying cancer p…

This study tests whether a daily pill called pirtobrutinib works better than the standard combination of bendamustine and rituximab for people with chronic lymphocytic leukemia or small lymphocytic lymphoma who have not yet been treated. About 309 participants will be randomly as…

This study tests whether adding a newer drug (venetoclax) to the standard two-drug therapy (ibrutinib plus obinutuzumab) helps older adults with untreated chronic lymphocytic leukemia (CLL) live longer without their cancer returning. It also explores whether patients who respond …

This study is observing about 90 adults with chronic lymphocytic leukemia (CLL) who are taking the drug acalabrutinib as part of their normal care in Russia. Researchers are collecting data from medical records to see how long patients live without their cancer getting worse and …

This early-phase study tested a combination of two drugs, daratumumab and ibrutinib, in 15 people with untreated chronic lymphocytic leukemia (CLL) who needed treatment. The goal was to see how safe the combination is and how well it works at controlling the disease. Participants…

This early-phase trial tests whether giving healthy donor NK cells along with two drugs (vactosertib and IL-2) is safe and helps the cells survive longer in people with advanced colorectal, stomach/esophageal, or blood cancers. About 12 participants will receive the combination t…

This study tests different dosing schedules for the drug sonrotoclax in 56 adults with chronic lymphocytic leukemia (CLL). The goal is to find a safer way to start treatment and reduce the risk of tumor lysis syndrome, a serious side effect. Participants receive sonrotoclax in gr…

This study tests a new drug called acalabrutinib for people with chronic lymphocytic leukemia (CLL) or related blood cancers. The goal is to see if the drug is safe and can shrink or control the cancer. Participants take the drug by mouth, and the study tracks side effects and ho…

This early-phase study tests a new type of immunotherapy called tri-specific CAR T-cells for people with B-cell lymphomas that have come back or not responded to treatment. The therapy is designed to target three different markers on cancer cells to improve effectiveness and redu…

This study tests a personalized treatment plan for young adults (18-65) with high-risk chronic lymphocytic leukemia (CLL) who have not had prior therapy. Patients first receive a combination of two drugs (venetoclax and obinutuzumab). Then, based on whether any cancer cells remai…

This early-phase study tests adding a targeted drug, loncastuximab tesirine, to the standard treatment acalabrutinib for people with chronic lymphocytic leukemia (CLL). The main goal is to find the safest dose of the combination. Researchers will also check if the combo can make …

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections while still preventing graft-versus-host disease (a condition where donor cells attack the patient's body). About 3…

This early-stage trial tests a new treatment for B-cell cancers (like leukemia and lymphoma) that haven't responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goal is to…

This early-phase study tests an experimental drug called ABBV-453 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to at least two prior treatments. Participants first receive a standard antibody (obinutuzum…

This early-phase study tests an experimental therapy called NKX019, made from donor immune cells (natural killer cells) engineered to target and kill cancer cells. It is for people with certain blood cancers (like lymphoma or leukemia) that have come back or not responded to othe…

This early-phase study tests a combination of two drugs, copanlisib and nivolumab, in people with Richter's transformation or certain non-Hodgkin lymphomas. The goal is to find the safest dose and see how well the drugs work together. About 27 adults will take part, and the study…

This early-phase trial tests a new treatment called huCART19-IL18 for people with certain blood cancers (leukemia and lymphoma) that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified to better find and attack cancer cel…

This early-phase trial tests whether vaccinating stem cell donors against cytomegalovirus (CMV) can help protect the transplant recipient from CMV infection. About 34 people with blood cancers receiving a donor stem cell transplant will have their donors vaccinated before donatio…

This study tests different programs to help people at high risk for cancer eat healthier and exercise more. The goal is to see which approach works best to increase physical activity and improve diet. About 337 people with a high BMI, low activity, or poor diet are taking part. T…

This study tests a drug called ruxolitinib (Jakafi) to see if it can reduce severe fatigue in people with chronic lymphocytic leukemia (CLL). The trial includes 10 patients who have CLL but do not yet need standard treatment. The goal is to improve quality of life by easing tired…

This study looks at whether exercise and weight management can help reduce fatigue in people who have had chronic lymphocytic leukemia (CLL). About 30 adults aged 18-85 with CLL who are not very active will take part. Participants will be randomly assigned to start the program ri…

This study looks at how chronic lymphocytic leukemia (CLL) patients in Romania are doing while taking the drug acalabrutinib in everyday medical practice, not in a strict research setting. Researchers will collect information from 250 patients' medical records over 3 years to see…

This study will observe how doctors in Russia treat chronic lymphocytic leukemia (CLL) in everyday practice, without giving any experimental treatments. About 6,000 adults with CLL will have their medical records reviewed for up to 2 years to see which therapies are used and how …

This study follows about 178 people who previously received an experimental AvenCell CAR-T cell therapy for blood cancers or prostate cancer. Researchers will monitor participants for years to check for delayed side effects, such as new cancers, nerve disorders, or severe infecti…

This study follows 50 people with chronic lymphocytic leukemia who are starting treatment with acalabrutinib or zanabrutinib. Participants use wearable devices at home to monitor their heart rhythm and blood pressure. The goal is to learn how often these drugs cause high blood pr…

This study looks for a blood test that can predict infection risk in people with chronic lymphocytic leukemia or multiple myeloma. Researchers will analyze blood samples from 150 adults to find markers linked to infections. The goal is to help doctors prevent serious infections i…

This study looks at how two types of oral treatments for chronic lymphocytic leukemia (CLL) affect patients' well-being and quality of life. About 146 adults in Spain who are already taking these medications will fill out questionnaires over 18 months. The goal is to understand h…

This study looks at how long people with chronic lymphocytic leukemia (CLL) stay on the drug acalabrutinib and why they might stop. It follows 350 patients from 70 French hospitals for up to 3 years, using medical records. The goal is to see how the drug performs in real life, no…

This study looked at the costs and quality-of-life benefits of three different drug combinations for older adults (65 and up) with chronic lymphocytic leukemia (CLL). Researchers compared a standard chemo-immunotherapy (bendamustine plus rituximab) with two newer ibrutinib-based …

This study looks at how blood cancers and stem cell transplants impact muscle function in 144 patients. Researchers want to see if muscle problems can help predict complications like infections, hospital stays, or survival. The goal is to better understand recovery and guide futu…

This study looks at people and families who may have a higher chance of getting blood cancers like leukemia or lymphoma. Researchers want to learn what genes or environmental factors might cause these cancers. Participants fill out health surveys and give blood or cheek cell samp…